105 results on '"Zillikens, M. C."'
Search Results
2. Disease Manifestations and Complications in Dutch X-Linked Hypophosphatemia Patients
- Author
-
Bosman, A., Appelman-Dijkstra, N. M., Boot, A. M., de Borst, M. H., van de Ven, A. C., de Jongh, R. T., Bökenkamp, A., van den Bergh, J. P., van der Eerden, B. C. J., and Zillikens, M. C.
- Published
- 2024
- Full Text
- View/download PDF
3. Sexual dimorphisms in serum calcium and phosphate concentrations in the Rotterdam Study
- Author
-
Bosman, Ariadne, Koek, W. Nadia H., Campos-Obando, Natalia, van der Eerden, Bram C. J., Ikram, M. A., Uitterlinden, André G., van Leeuwen, Johannes P. T. M., and Zillikens, M. C.
- Published
- 2023
- Full Text
- View/download PDF
4. Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan
- Author
-
Vandenput, L., Johansson, H., McCloskey, E. V., Liu, E., Åkesson, K. E., Anderson, F. A., Azagra, R., Bager, C. L., Beaudart, C., Bischoff-Ferrari, H. A., Biver, E., Bruyère, O., Cauley, J. A., Center, J. R., Chapurlat, R., Christiansen, C., Cooper, C., Crandall, C. J., Cummings, S. R., da Silva, J. A. P., Dawson-Hughes, B., Diez-Perez, A., Dufour, A. B., Eisman, J. A., Elders, P. J. M., Ferrari, S., Fujita, Y., Fujiwara, S., Glüer, C.-C., Goldshtein, I., Goltzman, D., Gudnason, V., Hall, J., Hans, D., Hoff, M., Hollick, R. J., Huisman, M., Iki, M., Ish-Shalom, S., Jones, G., Karlsson, M. K., Khosla, S., Kiel, D. P., Koh, W.-P., Koromani, F., Kotowicz, M. A., Kröger, H., Kwok, T., Lamy, O., Langhammer, A., Larijani, B., Lippuner, K., Mellström, D., Merlijn, T., Nordström, A., Nordström, P., O’Neill, T. W., Obermayer-Pietsch, B., Ohlsson, C., Orwoll, E. S., Pasco, J. A., Rivadeneira, F., Schei, B., Schott, A.-M., Shiroma, E. J., Siggeirsdottir, K., Simonsick, E. M., Sornay-Rendu, E., Sund, R., Swart, K. M. A., Szulc, P., Tamaki, J., Torgerson, D. J., van Schoor, N. M., van Staa, T. P., Vila, J., Wareham, N. J., Wright, N. C., Yoshimura, N., Zillikens, M. C., Zwart, M., Harvey, N. C., Lorentzon, M., Leslie, W. D., and Kanis, J. A.
- Published
- 2022
- Full Text
- View/download PDF
5. Hypercalcemia during pregnancy: management and outcomes for mother and child
- Author
-
Appelman-Dijkstra, Natasha M., Ertl, Diana- Alexandra, Zillikens, M. C., Rjenmark, Lars, and Winter, Elizabeth M.
- Published
- 2021
- Full Text
- View/download PDF
6. International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates
- Author
-
Diez-Perez, A., Naylor, K. E., Abrahamsen, B., Agnusdei, D., Brandi, M. L., Cooper, C., Dennison, E., Eriksen, E. F., Gold, D. T., Guañabens, N., Hadji, P., Hiligsmann, M., Horne, R., Josse, R., Kanis, J. A., Obermayer-Pietsch, B., Prieto-Alhambra, D., Reginster, J.-Y., Rizzoli, R., Silverman, S., Zillikens, M. C., Eastell, R., and Adherence Working Group of the International Osteoporosis Foundation and the European Calcified Tissue Society
- Published
- 2017
- Full Text
- View/download PDF
7. Arterial stiffness is not associated with bone parameters in an elderly hyperhomocysteinemic population
- Author
-
van Dijk, S. C., de Jongh, R. T., Enneman, A. W., Ham, A. C., Swart, K. M. A., van Wijngaarden, J. P., van der Zwaluw, N. L., Brouwer-Brolsma, E. M., van Schoor, N. M., Dhonukshe-Rutten, R. A. M., Lips, P., de Groot, C. P. G. M., Smulders, Y. M., Blom, H. J., Feskens, E. J., Geleijnse, J. M., van den Meiracker, A. H., Mattace Raso, F. U. S., Uitterlinden, A. G., Zillikens, M. C., and van der Velde, N.
- Published
- 2016
- Full Text
- View/download PDF
8. BMI and body fat mass is inversely associated with vitamin D levels in older individuals
- Author
-
Oliai Araghi, S., van Dijk, S. C., Ham, A. C., Brouwer-Brolsma, E. M., Enneman, A. W., Sohl, E., Swart, K. M. A., van der Zwaluw, N. L., van Wijngaarden, J. P., Dhonukshe-Rutten, R. A. M., van Schoor, N. M., Zillikens, M. C., Lips, P., de Groot, L., Uitterlinden, A. G., and van der Velde, Nathalie
- Published
- 2015
- Full Text
- View/download PDF
9. Dietary vitamin A intake and bone health in the elderly: the Rotterdam Study
- Author
-
de Jonge, E A L, Kiefte-de Jong, J C, Campos-Obando, N, Booij, L, Franco, O H, Hofman, A, Uitterlinden, A G, Rivadeneira, F, and Zillikens, M C
- Published
- 2015
- Full Text
- View/download PDF
10. Association of polymorphisms in the beta-2 adrenergic receptor gene with fracture risk and bone mineral density
- Author
-
Veldhuis-Vlug, A. G., Oei, L., Souverein, P. C., Tanck, M. W. T., Rivadeneira, F., Zillikens, M. C., Kamphuisen, P. W., Maitland - van der Zee, A.H., de Groot, M. C. H., Hofman, A., Uitterlinden, A. G., Fliers, E., de Boer, A., and Bisschop, P. H.
- Published
- 2015
- Full Text
- View/download PDF
11. Insulin-resistance and metabolic syndrome are related to executive function in women in a large family-based study
- Author
-
Schuur, M., Henneman, P., van Swieten, J. C., Zillikens, M. C., de Koning, I., Janssens, A. C. J. W., Witteman, J. C. M., Aulchenko, Y. S., Frants, R. R., Oostra, B. A., van Dijk, K. Willems, and van Duijn, C. M.
- Published
- 2010
12. Dissecting the relationship between high-sensitivity serum C-reactive protein and increased fracture risk: the Rotterdam Study
- Author
-
Oei, L., Campos-Obando, N., Dehghan, A., Oei, E. H. G., Stolk, L., van Meurs, J. B. J., Hofman, A., Uitterlinden, A. G., Franco, O. H., Zillikens, M. C., and Rivadeneira, F.
- Published
- 2014
- Full Text
- View/download PDF
13. Supplement to: PLS3 mutations in X-linked osteoporosis with fractures.
- Author
-
van Dijk, F S, Zillikens, M C, and Micha, D
- Published
- 2013
14. Measures of body composition and risk of heart failure in the elderly: The Rotterdam study
- Author
-
Van Lieshout, M. A. W., Verwoert, G. C., Mattace-Raso, F. U. S., Zillikens, M. C., Sijbrands, E. J., Deckers, J. W., Hofman, A., and Witteman, J. C. M.
- Published
- 2011
- Full Text
- View/download PDF
15. An RBP4 promoter polymorphism increases risk of type 2 diabetes
- Author
-
van Hoek, M., Dehghan, A., Zillikens, M. C., Hofman, A., Witteman, J. C., and Sijbrands, E. J. G.
- Published
- 2008
- Full Text
- View/download PDF
16. Heritability of fasting glucose levels in a young genetically isolated population
- Author
-
Santos, R. L. P., Zillikens, M. C., Rivadeneira, F. R., Pols, H. A. P., Oostra, B. A., van Duijn, C. M., and Aulchenko, Y. S.
- Published
- 2006
- Full Text
- View/download PDF
17. Lipoprotein receptor-related protein 1 variants and dietary fatty acids: meta-analysis of European origin and African American studies
- Author
-
Smith, C E, Ngwa, J, Tanaka, T, Qi, Q, Wojczynski, M K, Lemaitre, R N, Anderson, J S, Manichaikul, A, Mikkilä, V, van Rooij, F JA, Ye, Z, Bandinelli, S, Frazier-Wood, A C, Houston, D K, Hu, F, Langenberg, C, McKeown, N M, Mozaffarian, D, North, K E, Viikari, J, Zillikens, M C, Djoussé, L, Hofman, A, Kähönen, M, Kabagambe, E K, Loos, R JF, Saylor, G B, Forouhi, N G, Liu, Y, Mukamal, K J, Chen, Y-DI, Tsai, M Y, Uitterlinden, A G, Raitakari, O, van Duijn, C M, Arnett, D K, Borecki, I B, Cupples, L A, Ferrucci, L, Kritchevsky, S B, Lehtimäki, T, Qi, Lu, Rotter, J I, Siscovick, D S, Wareham, N J, Witteman, J CM, Ordovás, J M, and Nettleton, J A
- Published
- 2013
- Full Text
- View/download PDF
18. Menopause impacts the relation of plasma adiponectin levels with the metabolic syndrome
- Author
-
Henneman, P., Janssens, A. C. J. W., Zillikens, M. C., Frolich, M., Frants, R. R., Oostra, B. A., van Duijn, C. M., and van Dijk, Willems K.
- Published
- 2010
- Full Text
- View/download PDF
19. Erratum: Dietary vitamin A intake and bone health in the elderly: the Rotterdam Study
- Author
-
de Jonge, E A L, Kiefte-de Jong, J C, Campos-Obando, N, Booij, L, Franco, O H, Hofman, A, Uitterlinden, A G, Rivadeneira, F, and Zillikens, M C
- Published
- 2015
- Full Text
- View/download PDF
20. Heritability of the Function and Structure of the Arterial Wall: Findings of the Erasmus Rucphen Family (ERF) Study
- Author
-
Sayed-Tabatabaei, F A., van Rijn, M J.E., Schut, A F.C., Aulchenko, Y S., Croes, E A., Zillikens, M C., Pols, H A.P., Witteman, J C.M., Oostra, B A., and van Duijn, C M.
- Published
- 2005
- Full Text
- View/download PDF
21. The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia
- Author
-
HOOGERBRUGGE, N., JANSEN, H., DE HEIDE, L., ZILLIKENS, M. C., DECKERS, J. W., and BIRKENHÄGER, J. C.
- Published
- 1997
22. Alta prevalenza di fratture vertebrali in presenza di una normale densità minerale ossea nei pazienti con acromegalia controllata
- Author
-
Wassenaar, M. J. E., Biermasz, N. R., Hamdy, N. A. T., Zillikens, M. C., van Meurs, J. B. J., Rivadeneira, F., Hofman, A., Uitterlinden, A. G., Stokkel, M. P. M., Roelfsema, F., Kloppenburg, M., Kroon, H. M., Romijn, J. A., Pereira, A. M., and Cozzi, Renato
- Published
- 2011
- Full Text
- View/download PDF
23. Hypophosphatasia in adolescents and adults: overview of diagnosis and treatment.
- Author
-
Bianchi, M. L., Bishop, N. J., Guañabens, N., Hofmann, C., Jakob, F., Roux, C., and Zillikens, M. C.
- Subjects
INBORN errors of metabolism diagnosis ,ALKALINE phosphatase ,INBORN errors of metabolism ,METALS in the body ,GENETIC mutation ,PROFESSIONS ,RARE diseases ,SEVERITY of illness index ,SYMPTOMS ,ADOLESCENCE ,ADULTS - Abstract
This article provides an overview of the current knowledge on hypophosphatasia—a rare genetic disease of very variable presentation and severity—with a special focus on adolescents and adults. It summarizes the available information on the many known mutations of tissue-nonspecific alkaline phosphatase (TNSALP), the epidemiology and clinical presentation of the disease in adolescents and adults, and the essential diagnostic clues. The last section reviews the therapeutic approaches, including recent reports on enzyme replacement therapy (EnzRT). [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
24. Effect Of A Late Evening Meal On Nitrogen Balance In Patients With Cirrhosis Of The Liver
- Author
-
Swart, G. R., Zillikens, M. C., van Vuure, J. K., and van den Berg, J. W. O.
- Published
- 1989
25. Vitamin D status and metabolic syndrome in the elderly: the Rotterdam Study.
- Author
-
Vitezova, A., Zillikens, M. C., van Herpt, T. T. W., Sijbrands, E. J. G., Hofman, A., Uitterlinden, A. G., Franco, O. H., and Kiefte-de Jong, J. C.
- Subjects
- *
VITAMIN D in the body , *METABOLIC syndrome , *DISEASES in older people , *TRIGLYCERIDES , *BLOOD pressure , *VITAMIN D receptors , *PATIENTS - Abstract
Objective: The effects of vitamin D in the elderly are inconsistent. The aim of this study was to evaluate the association between vitamin D status and the metabolic syndrome (MetS) in the elderly, as well as between vitamin D status and the components of MetS (i.e. serum glucose, triglycerides (TG), HDL cholesterol (HDL-C), waist circumference (WC), and blood pressure (BP)). Methods: The study was embedded in the Rotterdam Study, a population-based cohort of middle-aged and elderly adults. We analyzed data from 3240 people (median age 71.2 years) who did not have type 2 diabetes mellitus at baseline. Results: We found higher 25-hydroxyvitamin D (25(OH)D) concentrations associated with lower prevalence of MetS (odds ratio (OR); 95% CI: 0.61; 0.49, 0.77 for adequate levels (>75 nmol/l) vs deficiency (<50 nmol/l). In addition, in analysis of the individual components, the ORs for adequate vs deficient vitamin D levels were: 0.66 (95% CI 0.53, 0.83) for elevated WC, 0.67 (95% CI 0.52, 0.86) for reduced HDL-C, 0.69 (95% CI 0.54, 0.88) for elevated TG, and 0.80 (95% CI 0.65, 0.99) for elevated fasting glucose. Vitamin D was not associated with elevated blood pressure, and ORs for adequacy vs deficiency I were 0.82 (95% CI 0.65, 1.03). Conclusion: Higher 25(OH)D concentrations in the elderly are associated with lower prevalence of MetS and, in particular, with more beneficial HDL-C, TG, WC, and serum glucose. Since the prevalence of vitamin D deficiency is common worldwide and its risk increases with age, if causality is proven, benefits of improving vitamin D status among the elderly may be great. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
26. The effect of thiazide and loop diuretics on urinary levels of free deoxypyridinoline: an osteoclastic bone-resorption marker.
- Author
-
Ruiter, R., Oei, L., Visser, L. E., Peltenburg, H. G., Hofman, A., Zillikens, M. C., Uitterlinden, A. G., Rivadeneira, F., and Stricker, B. H.
- Subjects
AMINO acids ,ANALYSIS of variance ,BIOMARKERS ,BONE resorption ,CHI-squared test ,CONFIDENCE intervals ,DIURETICS ,LONGITUDINAL method ,REGRESSION analysis ,BONE density ,DATA analysis software ,DESCRIPTIVE statistics ,PHARMACODYNAMICS - Abstract
What is known and Objective Diuretics can cause changes in calcium levels due to renal effects. Moreover, calcium levels can also vary as a result of changes in intestinal absorption and in the activity of osteoclastic cells. A marker of osteoclastic bone-resorption activity is the level of urinary free deoxypyridinoline ( FDP). Deoxypyridinoline ( DP) acts as a cross-link between adjacent collagen chains to provide structural rigidity. Our aim was to investigate the association between use of thiazides and loop diuretics and urinary levels FDP. Methods In this follow-up study, data were obtained from the Rotterdam Study, a large population-based prospective cohort study. For a subset of 658 participants, urinary levels of FDP were measured at baseline. Linear regression analysis was performed to assess the association between the use of thiazides and loop diuretics and the urinary levels of FDP. Results In women, current use of loop diuretics for less than 42 days was associated with an increased level of urinary FDP (+3·43 nmol deoxypyridinoline per mmol urinary creatinine; 95% CI 1·85; 5·02) compared with no use. However, use for a period of more than 42 days was not associated with an increased level of FDP, nor was past use of loop diuretics. For thiazide diuretics, no statistically significant associations were found. What is new and Conclusion In women, short-term use of loop diuretics is associated with an increased level of FDP, reflecting increased bone resorption by osteoclasts. As the difference disappears with longer term use, the clinical significance is unclear and the value of FDP as a biomarker in this setting is not established. The molecular mechanism for the observed differences in bone fracture rates with use of diuretics remains unclear. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
27. Body composition by dual-energy X-ray absorptiometry in women with previous pre-eclampsia or small-for-gestational-age offspring.
- Author
-
Berends, A. L., Zillikens, M. C., de Groot, C. J. M., Rivadeneira, F., Oostra, B. A., van Duijn, C. M., and Steegers, E. A. P.
- Subjects
- *
EMBRYOLOGY , *ECLAMPSIA , *GESTATIONAL age , *OBSTETRICS , *PREGNANCY - Abstract
Objective To investigate differences in body composition and fat distribution between women with previous pre-eclampsia or small-for-gestational-age (SGA) offspring and those with uncomplicated pregnancies. Design Cohort study. Setting Population-based study in a genetically isolated population in the southwest of the Netherlands. Population Women after pregnancies complicated by pre-eclampsia ( n=45), SGA offspring ( n=53) and uncomplicated pregnancies ( n=106). Methods Women were compared for body composition and fat distribution variables, assessed by dual-energy X-ray absorptiometry (DXA) and anthropometrics at a mean follow-up time of 10.8 (SD ±5.9) years after pregnancy. Main outcome measures Total lean and fat mass, android fat mass, gynoid fat mass, android-to-gynoid fat ratio, waist and hip circumference, waist-to-hip ratio. Results Women with previous pre-eclampsia compared with controls had higher mean total fat mass index (11.5 ± 0.6 versus 9.7 ± 0.4 kg/m2; P = 0.03), lean mass index (15.8 ± 0.3 versus 14.5 ± 0.2 kg/m2; P =0.001) and body mass index ([BMI]; 28.4 ± 0.8 versus 25.4 ± 0.5 kg/m2; P = 0.005). Their waist circumferences (90.7 ± 2.0 versus 78.5 ± 1.3 cm; P < 0.001) and waist-to-hip ratios (0.86 ± 0.01 versus 0.77 ± 0.01; P < 0.001) were also higher as well as android fat mass (2.8 ± 0.2 versus 2.1 ± 0.1 kg; P = 0.01) and android-to-gynoid fat ratios (0.45 ± 0.02 versus 0.39 ± 0.01; P = 0.02). Mean total fat, lean and BMI was not significantly different between women with previous SGA offspring and controls, yet waist-to-hip ratios (0.83 ± 0.01; P < 0.001) were higher. The observed differences in waist and hip circumference, waist-to-hip ratio and gynoid fat mass could not be attributed to differences in BMI. Conclusion Women with previous pre-eclampsia or SGA offspring pregnancies compared with those with uncomplicated pregnancies have a preferential fat accumulation in the abdominal over hip region, which may explain, at least partly, their increased cardiovascular risk. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
28. Heritability of Serum Iron, Ferritin and Transferrin Saturation in a Genetically Isolated Population, the Erasmus Rucphen Family (ERF) Study.
- Author
-
Njajou, O. T, Alizadeh, B. Z, Aulchenko, Y., Zillikens, M. C., Pols, H. A. P., Oostra, B. A., Swinkels, D. W., and van Duijn, C. M.
- Subjects
HEMOCHROMATOSIS ,IRON ,FERRITIN ,TRANSFERRIN ,GENETIC disorders ,GENOTYPE-environment interaction - Abstract
Background: Iron has been implicated in the pathogenesis of various disorders. Mutations in the HFE gene are associated with an increase in serum iron parameters. The aim of this study was to estimate the heritability in serum iron parameters explained by HFE. Methods: Ninety families (980 subjects) were included in the present analysis. Heritability estimation was conducted using the variance component method. The likelihood ratio test was used to compare models. Phenotypic and genetic correlations between serum iron parameters were calculated. Results: The heritability (h
2 ± SE) estimates were 0.23 ± 0.07 (p < 0.0001) for iron, 0.29 ± 0.09 (p < 0.0001) for ferritin and 0.28 ± 0.07 (p < 0.0001) for transferrin saturation while adjusting for age, age2 and sex. The HFE genotypes explained between 2 to 6% of the sex and age-adjusted variance in serum iron, ferritin and transferrin saturation. There was a high genetic correlation between serum iron parameters, suggesting pleiotropy between these traits. Conclusion: A substantial proportion of the variance of iron, ferritin and transferrin saturation can be explained by additive genetic effects, independent of sex and age. The HFE genotypes explained a considerable proportion of serum iron parameters and may be an important factor in the complex iron network. Copyright © 2006 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]- Published
- 2006
- Full Text
- View/download PDF
29. Effects of the glucosidase inhibitor acarbose in patients with liver cirrhosis.
- Author
-
ZILLIKENS, M. C., SWART, G. R., BERG, J. W. O., and WILSON, J. H. P.
- Published
- 1989
- Full Text
- View/download PDF
30. A Genomewide Metaanalysis of the Combined Influence of Physical Activity and Genetic Variants on Body Fat Distribution in 94,779 Individuals of European Descent.
- Author
-
Graff, Mariaelisa, Xue, L., Kilpeläinen, Tuomas O., Justice, Anne, Winkler, Thomas, Young, Kristin L., Scott, Robert, Qibin Qi, Hadley, David, Mahajan, Anubha, Ahluwalia, Tarunveer S., Chu, Audrey Y., Czajkowski, Jacek, Lu Qi, Ngwa, Julius, Haller, Toomas, Monda, Keri L., Zillikens, M. C., Grove, Megan, and Heard-Costa, Nancy L.
- Published
- 2014
31. THE INFLUENCE OF GENETIC AND ENVIRONMENTAL FACTORS ON BLOOD PRESSURE VARIANCE IN A GENETICALLY ISOLATED POPULATION.
- Author
-
Schut, A. F.C., Deinum, J., Aulchenko, Y. S., Croes, E. A., Zillikens, M. C., Pols, H. A.P., Witteman, J. C.M., Oostra, B. A., and Van Duijn, C. M.
- Published
- 2004
- Full Text
- View/download PDF
32. FREQUENCY AND HERITABILITY OF THE METABOLIC SYNDROME IN A GENETICALLY ISOLATED POPULATION.
- Author
-
Schut, A. F.C., Deinum, J., Aulchenko, Y. S., Croes, E. A., Zillikens, M. C., Pols, H. A.P., Witteman, J. C.M., Oostra, B. A., and Van Duijn, C. M.
- Published
- 2004
- Full Text
- View/download PDF
33. Anthropometry in blacks: applicability of generalized skinfold equations and differences in fat patterning between blacks and whites
- Author
-
Conway, J. M. and Zillikens, M. C.
- Subjects
HUMAN body composition ,ANTHROPOMETRY - Published
- 1990
- Full Text
- View/download PDF
34. Previous fracture and subsequent fracture risk: a meta-analysis to update FRAX.
- Author
-
Kanis JA, Johansson H, McCloskey EV, Liu E, Åkesson KE, Anderson FA, Azagra R, Bager CL, Beaudart C, Bischoff-Ferrari HA, Biver E, Bruyère O, Cauley JA, Center JR, Chapurlat R, Christiansen C, Cooper C, Crandall CJ, Cummings SR, da Silva JAP, Dawson-Hughes B, Diez-Perez A, Dufour AB, Eisman JA, Elders PJM, Ferrari S, Fujita Y, Fujiwara S, Glüer CC, Goldshtein I, Goltzman D, Gudnason V, Hall J, Hans D, Hoff M, Hollick RJ, Huisman M, Iki M, Ish-Shalom S, Jones G, Karlsson MK, Khosla S, Kiel DP, Koh WP, Koromani F, Kotowicz MA, Kröger H, Kwok T, Lamy O, Langhammer A, Larijani B, Lippuner K, Mellström D, Merlijn T, Nordström A, Nordström P, O'Neill TW, Obermayer-Pietsch B, Ohlsson C, Orwoll ES, Pasco JA, Rivadeneira F, Schott AM, Shiroma EJ, Siggeirsdottir K, Simonsick EM, Sornay-Rendu E, Sund R, Swart KMA, Szulc P, Tamaki J, Torgerson DJ, van Schoor NM, van Staa TP, Vila J, Wareham NJ, Wright NC, Yoshimura N, Zillikens MC, Zwart M, Vandenput L, Harvey NC, Lorentzon M, and Leslie WD
- Subjects
- Male, Humans, Female, Bone Density, Risk Factors, Risk Assessment, Osteoporotic Fractures etiology, Osteoporotic Fractures complications, Osteoporosis complications, Hip Fractures etiology, Hip Fractures complications
- Abstract
A large international meta-analysis using primary data from 64 cohorts has quantified the increased risk of fracture associated with a previous history of fracture for future use in FRAX., Introduction: The aim of this study was to quantify the fracture risk associated with a prior fracture on an international basis and to explore the relationship of this risk with age, sex, time since baseline and bone mineral density (BMD)., Methods: We studied 665,971 men and 1,438,535 women from 64 cohorts in 32 countries followed for a total of 19.5 million person-years. The effect of a prior history of fracture on the risk of any clinical fracture, any osteoporotic fracture, major osteoporotic fracture, and hip fracture alone was examined using an extended Poisson model in each cohort. Covariates examined were age, sex, BMD, and duration of follow-up. The results of the different studies were merged by using the weighted β-coefficients., Results: A previous fracture history, compared with individuals without a prior fracture, was associated with a significantly increased risk of any clinical fracture (hazard ratio, HR = 1.88; 95% CI = 1.72-2.07). The risk ratio was similar for the outcome of osteoporotic fracture (HR = 1.87; 95% CI = 1.69-2.07), major osteoporotic fracture (HR = 1.83; 95% CI = 1.63-2.06), or for hip fracture (HR = 1.82; 95% CI = 1.62-2.06). There was no significant difference in risk ratio between men and women. Subsequent fracture risk was marginally downward adjusted when account was taken of BMD. Low BMD explained a minority of the risk for any clinical fracture (14%), osteoporotic fracture (17%), and for hip fracture (33%). The risk ratio for all fracture outcomes related to prior fracture decreased significantly with adjustment for age and time since baseline examination., Conclusion: A previous history of fracture confers an increased risk of fracture of substantial importance beyond that explained by BMD. The effect is similar in men and women. Its quantitation on an international basis permits the more accurate use of this risk factor in case finding strategies., (© 2023. International Osteoporosis Foundation and Bone Health and Osteoporosis Foundation.)
- Published
- 2023
- Full Text
- View/download PDF
35. The prevalence of osteopenia and osteoporosis after heart transplantation assessed using CT.
- Author
-
Roest S, Budde RPJ, Hesselink DA, Zijlstra F, Zillikens MC, Caliskan K, Bos D, and Manintveld OC
- Subjects
- Humans, Female, Middle Aged, Male, Prevalence, Bone Density, Absorptiometry, Photon methods, Tomography, X-Ray Computed methods, Lumbar Vertebrae, Retrospective Studies, Osteoporosis diagnostic imaging, Osteoporosis epidemiology, Bone Diseases, Metabolic diagnostic imaging, Bone Diseases, Metabolic epidemiology, Heart Transplantation adverse effects
- Abstract
Objective: Osteoporosis is frequently observed in patients after heart transplantation (HT), although the prevalence long-term post-HT is unknown. Most studies investigating bone mineral density (BD) after HT were performed using dual-energy X-ray absorptiometry. In this study BD, including the prevalence of osteopenia and osteoporosis, was investigated using coronary computed tomography (CCT) long-term post-HT. Moreover, risk factors for abnormal BD were investigated., Methods: All first CCT scans between February 2018 and June 2020 used for the annual screening for cardiac allograft vasculopathy were included. Retransplantations and scans with not fully imaged vertebrae were excluded. BD was measured as a mean of the BD of three consecutive thoracic vertebrae and categorized into normal BD, osteopenia or osteoporosis. Binary logistic regression was used to find determinants for an abnormal BD. Linear regression was used to explore determinants for the mean Hounsfield unit (HU) value of the BD., Results: In total, 140 patients were included (median age 55.2 [42.9-64.9] years, 51 (36%) female). Time between HT and CT scan was 11.0 [7.3-16.1] years. In total, 80 (57%), 43 (31%), and 17 (12%) patients had a normal BD, osteopenia, or osteoporosis, respectively. Osteoporotic fracture or vertebrae fractures was seen in 11 (8%) patients. Determinants for an abnormal BD were recipient age (OR 1.10 (1.06-1.14), p<0.001) and prednisolone use (OR 3.75 (1.27-11.01), p=0.016). In linear regression, left ventricular assist device use pre-HT (p=0.024) and time since HT (p=0.046) were additional BD determinants., Discussion: Osteopenia and osteoporosis are frequently seen on CCT post-HT. More investigation on appropriate measures to maintain a normal BD in these patients are needed., (Copyright © 2023. Published by Elsevier Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
36. Skin autofluorescence, a non-invasive biomarker of advanced glycation end products, and its relation to radiographic and MRI based osteoarthritis.
- Author
-
Waqas K, Szilagyi IA, Schiphof D, Boer CG, Bierma-Zeinstra S, van Meurs JBJ, and Zillikens MC
- Subjects
- Male, Humans, Female, Glycation End Products, Advanced, Magnetic Resonance Imaging methods, Biomarkers, Skin, Osteoarthritis, Knee diagnostic imaging, Cartilage, Articular diagnostic imaging
- Abstract
Objectives: Accumulation of advanced glycation end products (AGEs) in articular cartilage during aging has been proposed as a mechanism involved in the development of osteoarthritis (OA). Therefore, we investigated a cross-sectional relationship between skin AGEs, a biomarker for systemic AGEs accumulation, and OA., Methods: Skin AGEs were estimated with the AGE Reader™ as skin autofluorescence (SAF). Knee and hip X-rays were scored according to Kellgren and Lawrence (KL) system. KL-sum score of all four joints was calculated per participant to assess severity of overall radiographic OA (ROA) including or excluding those with prosthesis. Knee MRI of tibiofemoral joint (TF
MRI ) was assessed for cartilage loss. Sex-stratified regression models were performed after testing interaction with SAF., Results: 2,153 participants were included for this cross-sectional analysis. In women (n = 1,206) for one unit increase in SAF, the KL-sum score increased by 1.15 (95% confidence interval = 1.00-1.33) but excluding women with prosthesis, there was no KL-sum score increase [0.96 (0.83-1.11)]. SAF was associated with higher prevalence of prosthesis [Odds ratio, OR = 1.67 (1.10-2.54)] but not with ROA [OR = 0.83 (0.61-1.14)] when compared to women with no ROA. In men (n = 947), there was inconclusive association between SAF and KL sum score or prosthesis. For TFMRI (n = 103 women), SAF was associated with higher prevalence of cartilage loss, full-thickness [OR = 5.44 (1.27-23.38)] and partial-thickness [OR = 1.45 (0.38-5.54)], when compared to participants with no cartilage loss., Conclusion: Higher SAF in women was associated with higher prosthesis prevalence and a trend towards higher cartilage loss on MRI. Our data presents inconclusive results between SAF and ROA in both sexes., (Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
37. Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer.
- Author
-
Waqas K, Lima Ferreira J, Tsourdi E, Body JJ, Hadji P, and Zillikens MC
- Abstract
Introduction: Adjuvant endocrine therapy induces bone loss and increases fracture risk in women with hormone-receptor positive, early-stage breast cancer (EBC). We aimed to update a previous position statement on the management of aromatase inhibitors (AIs) induced bone loss and now included premenopausal women., Methods: We conducted a systematic literature search of the medical databases from January 2017 to May 2020 and assessed 144 new studies., Results: Extended use of AIs beyond 5 years leads to persistent bone loss in breast cancer extended adjuvant trials and meta -analyses. In addition to bone mineral density (BMD), vertebral fracture assessment (VFA) and trabecular bone score (TBS) were shown to independently predict fracture risk in real life prospective studies. FRAX® tool does not seem to be reliable for assessing fracture risk in CTIBL. In premenopausal women, there is strong evidence that intravenous zoledronate prevents bone loss but weak conflicting evidence on reducing disease recurrence from independent randomised controlled trials (RCTs). In postmenopausal women, the strongest evidence for fracture prevention is for denosumab based on a well-powered RCT while there is strong evidence for bisphosphonates (BPs) to prevent and reduce CTIBL but no convincing data on fractures. Adjuvant denosumab has failed to show anticancer benefits in a large, well-designed RCT., Discussion and Conclusions: Extended use of AIs and persistent bone loss from recent data reinforce the need to evaluate fracture risk in EBC women initiated on AIs. Fracture risk should be assessed with clinical risk factors and BMD along with VFA, but FRAX is not adapted to CTIBL. Anti-resorptive therapy should be considered in those with a BMD T-score < -2.0 SD or with ≥ 2 clinical risk factors including a BMD T-score < -1.0 SD. In premenopausal women, intravenous zoledronate is the only drug reported to prevent bone loss and may have additional anticancer benefits. In postmenopausal women, either denosumab or BPs can be prescribed for fracture prevention with pertinent attention to the rebound phenomenon after stopping denosumab. Adjuvant BPs, in contrast to denosumab, have shown high level evidence for reducing breast cancer recurrence in high-risk post-MP women which should be taken into account when choosing between these two., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2021 The Authors.)
- Published
- 2021
- Full Text
- View/download PDF
38. Age-dependent sex differences in calcium and phosphate homeostasis.
- Author
-
Koek WNH, Campos-Obando N, van der Eerden BCJ, de Rijke YB, Ikram MA, Uitterlinden AG, van Leeuwen JPTM, and Zillikens MC
- Abstract
Background: Sex differences in calcium and phosphate have been observed. We aimed to assess a relation with age., Methods: We used the laboratory values of serum calcium, phosphate and albumin from three different samples ( 2005, 2010 and 2014 years) using the hospital information system of Erasmus MC, Rotterdam. The samples were divided into three age groups: 1-17, 18-44 and ≥45 years. Sex differences in calcium and phosphate were analyzed using ANCOVA, adjusting for age and serum albumin. Furthermore, sex by age interactions were determined and we analyzed differences between age groups stratified by sex., Results: In all three samples there was a significant sex × age interaction for serum calcium and phosphate, whose levels were significantly higher in women compared to men above 45 years. No sex differences in the younger age groups were found. In men, serum calcium and phosphate levels were highest in the youngest age group compared to age groups of 18-44 and ≥45 years. In women, serum calcium levels were significantly higher in the age group 1-17 and the age group ≥45 years compared to the 18-44 years age group. In women, serum phosphate was different between the three different age groups with highest level in the group 1-17 years and lowest in the group 18-44 years., Conclusion: There are age- dependent sex differences in serum calcium and phosphate. Furthermore, we found differences in serum calcium and phosphate between different age groups. Underlying mechanisms for these age- and sex- differences are not yet fully elucidated.
- Published
- 2021
- Full Text
- View/download PDF
39. Vitamin D serum levels are cross-sectionally but not prospectively associated with late-life depression.
- Author
-
Jovanova O, Aarts N, Noordam R, Zillikens MC, Hofman A, and Tiemeier H
- Subjects
- Age of Onset, Cross-Sectional Studies, Depression complications, Depression etiology, Diagnostic and Statistical Manual of Mental Disorders, Humans, Prospective Studies, Vitamin D metabolism, Depression metabolism, Vitamin D analogs & derivatives, Vitamin D Deficiency metabolism
- Abstract
Objective: The evidence for a prospective association of vitamin D deficiency with the occurrence of late-life depression is limited. We aimed to study the long-term association between vitamin D serum levels and depression in a large population-based study of older adults., Method: We included 3251 participants from the Rotterdam Study, aged 55 and older with 32 400 person-years follow-up for depression. Baseline 25-hydroxyvitamin D (25(OH)D) serum levels were analyzed continuously and categorically. Repeated depressive symptoms' questionnaire assessments were used to assess the change of depressive symptoms. Semistructured psychiatric interviews, and GP records were used to assess incident major depressive disorder according to DSM-IV criteria., Results: Low serum vitamin D levels were cross-sectionally associated with more depressive symptoms. However, low 25(OH)D serum levels were not prospectively associated with change of depressive symptoms (unstandardized beta = 0.02, 95% CI = -0.23; 0.26) or incident MDD (hazard ratio = 0.95, 95% CI = 0.86; 1.05)., Conclusion: We observed a cross-sectional but no prospective association between serum vitamin D levels and depression. A cross-sectional association in the absence of the longitudinal association can mostly be attributed to reverse causality or residual confounding. Probably, vitamin D deficiency is not an independent risk factor for depression but co-occurs with late-life depression., (© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
40. Osteoclastogenic capacity of peripheral blood mononuclear cells is not different between women with and without osteoporosis.
- Author
-
Koek WNH, van der Eerden BCJ, Alves RDAM, van Driel M, Schreuders-Koedam M, Zillikens MC, and van Leeuwen JPTM
- Subjects
- Aged, Bone Resorption pathology, Case-Control Studies, Cell Differentiation, Female, Humans, Osteoporosis drug therapy, Osteoporotic Fractures drug therapy, Osteoporotic Fractures pathology, Leukocytes, Mononuclear metabolism, Osteoclasts pathology, Osteogenesis, Osteoporosis blood, Osteoporosis pathology
- Abstract
Introduction: Peripheral Blood Mononuclear Cells (PBMCs) have been extensively used as a culture model to generate osteoclasts in vitro. The aim of this study was to assess the osteoclastogenic potential of PBMCs derived from post-menopausal women with longstanding osteoporosis and compare this with PBMCs from healthy controls., Material and Methods: We selected from the population-based Rotterdam Study 82 participants of which 43 were diagnosed with osteoporosis (T-score below -2.5 at the lumbar spine) and the presence of at least 1 fracture and 29 healthy controls (T-score above 1; no fracture). PBMCs were differentiated into osteoclasts, and both differentiation capacity and activity were measured. Total RNA was obtained to assess gene expression of osteoclast markers. Deoxypyridinoline (DPD) was measured in plasma as a marker for bone resorption, in vivo., Results: Neither the number of osteoclasts nor cathepsin K (CTSK) and dendritic cell-specific transmembrane protein (TM7SF4) gene expression was significantly different between both groups. There was also no significant difference in resorption pit area and plasma DPD levels. Stratification by fracture type into a group with vertebral, non-vertebral and both vertebral and non-vertebral fractures showed no difference in osteoclast formation or osteoclastic bone resorption. However, plasma DPD, but not the RNA expression markers, was significantly lower in the group of subjects with vertebral fracture group and those with vertebral and non-vertebral fractures compared to the healthy controls. No differences in osteoclastogenesis, osteoclastic resorption and plasma DPD levels were detected also after exclusion of past or present users of bisphosphonates and glucocorticoids. Stratification into high and low DPD levels showed higher osteoclastogenesis and more osteoclastic bone resorption in the high DPD group compared to the low DPD levels within the group of osteoporotic subjects., Conclusion: This study showed no difference in PBMC osteoclastogenic capacity and activity between women with and without osteoporosis and at least one previous fracture, who were on average 29.5years after menopause, suggesting that there is no difference in circulating osteoclast precursors. Although we cannot exclude that circulating precursors may behave differently at the bone site, it is possible that long after menopause a more stable phase of bone turnover is reached compared to earlier after the start of menopause in which differences in circulating osteoclast precursors and osteoclastogenic potential are more prominent., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
41. Associations of vitamin D status and vitamin D-related polymorphisms with sex hormones in older men.
- Author
-
Rafiq R, van Schoor NM, Sohl E, Zillikens MC, Oosterwerff MM, Schaap L, Lips P, and de Jongh RT
- Subjects
- Adult, Aged, Aged, 80 and over, Body Mass Index, Cohort Studies, Estradiol blood, Follicle Stimulating Hormone blood, Genotype, Humans, Hypogonadism blood, Longitudinal Studies, Luteinizing Hormone blood, Male, Middle Aged, Netherlands, Polymorphism, Single Nucleotide, Prospective Studies, Reproducibility of Results, Sex Hormone-Binding Globulin metabolism, Testosterone blood, Vitamin D blood, Vitamin D genetics, Young Adult, Gonadal Steroid Hormones blood, Polymorphism, Genetic, Receptors, Calcitriol blood, Receptors, Calcitriol genetics, Vitamin D analogs & derivatives
- Abstract
Objective: Evidence regarding relationships of serum 25-hydroxyvitamin D (25(OH)D) with sex hormones and gonadotropin concentrations remains inconsistent. Polymorphisms in vitamin D-related genes may underly these relationships. Our aim was to examine the relationship of vitamin D status and polymorphisms in vitamin D-related genes with sex hormone and gonadotropin levels., Design and Measurements: We analysed data from the Longitudinal Aging Study Amsterdam, an ongoing population-based cohort study of older Dutch individuals (65-89 years). We included data of men with measurements of serum 25-hydroxyvitamin D (25(OH)D) (n=643) and determination of vitamin D-related gene polymorphisms (n=459). 25(OH)D concentrations were classified into four categories: <25, 25-50, 50-75 and >75nmol/L. Outcome measures were total testosterone, calculated bioavailable and free fraction testosterone, SHBG, estradiol, LH and FSH concentrations. Hypogonadism was defined as a total testosterone level <8.0nmol/L., Results: Serum 25(OH)D was positively associated with total and bioavailable testosterone levels. After adjustments for confounders, men with serum 25(OH)D less than 25 (n=56), 25-50 (n=199) and 50-75nmol/L (n=240) had lower total testosterone levels compared to men with serum 25(OH)D higher than 75nmol/L (n=148) (β (95% confidence interval): -2.1 (-3.7 to -0.4nmol/L), -0.8 (-1.9 to 0.4nmol/L) and -1.4 (-2.4 to -0.3nmol/L), respectively). For bioavailable testosterone the association was significant only for men with serum 25(OH)D less than 25nmol/L (-0.8 (-1.4 to -0.1nmol/L)) compared to men with serum 25(OH)D >75nmol/L. Serum 25(OH)D was not related to SHBG, estradiol or gonadotropin levels. Hypogonadism (n=29) was not associated with lower serum 25(OH)D. No significant differences were found in hormone levels between the different genotypes of the vitamin D-related gene polymorphisms. Also, the polymorphisms did not modify the relationships of serum 25(OH)D with sex hormones or gonadotropins., Conclusion: Vitamin D status is positively associated with testosterone levels. No association was found between vitamin D-related gene polymorphisms and hormone levels., (Copyright © 2015 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
42. [Paget's disease of bone: diagnosis and treatment].
- Author
-
Winter EM, Hamdy NA, de Jongh RT, Eekhoff EM, Zillikens MC, and Appelman-Dijkstra NM
- Subjects
- Aged, Bone Density Conservation Agents therapeutic use, Diphosphonates therapeutic use, Humans, Imidazoles therapeutic use, Male, Middle Aged, Osteitis Deformans drug therapy, Zoledronic Acid, Osteitis Deformans diagnostic imaging
- Abstract
Paget's disease of bone is a focal disorder of bone remodelling that leads to changes in the shape and size of affected bones, and is associated with articular and vascular complications. The disorder is characterised by a localised increase in osteoclast number and activity in one or more affected sites while the rest of the skeleton remains unaffected. The excessive bone resorption leads to recruitment of osteoblasts to the remodelling sites, resulting in increased bone formation. This accelerated bone turnover causes deposition of bone with disorganised architecture and structural weakness. The precise aetiology is unknown. It is thought that the disease is caused by interactions between environmental and genetic factors; the nature of this interaction still has to be determined. The disease is progressive, but can be treated with a single infusion of zoledronic acid. In this manuscript three cases are described, along with a review of the current diagnostic tools and treatment.
- Published
- 2016
43. Bidirectional associations between circulating vitamin D and cholesterol levels: The Rotterdam Study.
- Author
-
Vitezova A, Voortman T, Zillikens MC, Jansen PW, Hofman A, Uitterlinden AG, Franco OH, and Kiefte-de Jong JC
- Subjects
- Aged, Aged, 80 and over, Cholesterol, HDL blood, Female, Humans, Male, Middle Aged, Models, Statistical, Netherlands, Prospective Studies, Vitamin D blood, Cholesterol blood, Vitamin D analogs & derivatives, Vitamin D Deficiency blood
- Abstract
Objectives: Higher levels of vitamin D have been associated with lower rates of cardiovascular disease perhaps through improved lipid profiles. However, results are inconsistent and the direction of the association between vitamin D and lipid levels remains unknown. We examined bidirectional associations between serum 25-hydroxyvitamin D (25(OH)D) and cholesterol concentrations., Study Design: We used data from 1165 participants aged 55 to 88 years from the Rotterdam Study, a population-based prospective cohort study., Main Outcome Measures: Serum concentrations of 25(OH)D, total cholesterol (TC) and HDL cholesterol (HDL-C) were measured at two time points with a median time difference of 6 years. Bidirectional associations between 25(OH)D and each of the blood lipids was examined with path analyses in cross-lagged models. All models were adjusted for baseline age, sex, BMI, smoking status, and diet quality., Results: The best-fit model for 25(OH)D and TC indicated that higher baseline TC concentrations were associated with lower 25(OH)D concentrations (standardized regression coefficient -0.05 (SE 0.02)), but 25(OH)D at baseline did not predict TC. For HDL-C, the best-fit model suggested a bidirectional inverse association between HDL-C and 25(OH)D (standardized regression coefficients of -0.03 (SE 0.02)) for both directions., Conclusions: Our results from path analyses on repeatedly measured 25(OH)D and lipid levels suggest that total cholesterol may be associated with decreased in 25(OH)D concentrations, but not the other way around, whereas the observed inverse association between HDL-C and 25(OH)D may be bidirectional., (Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
44. The association between plasma homocysteine levels and bone quality and bone mineral density parameters in older persons.
- Author
-
Enneman AW, Swart KM, Zillikens MC, van Dijk SC, van Wijngaarden JP, Brouwer-Brolsma EM, Dhonukshe-Rutten RA, Hofman A, Rivadeneira F, van der Cammen TJ, Lips P, de Groot CP, Uitterlinden AG, van Meurs JB, van Schoor NM, and van der Velde N
- Subjects
- Absorptiometry, Photon, Aged, Aged, 80 and over, Cross-Sectional Studies, Female, Femur Neck metabolism, Humans, Male, Middle Aged, Bone Density physiology, Homocysteine blood
- Abstract
Introduction: High plasma homocysteine levels have been associated with incident osteoporotic fractures, but the mechanisms underlying this association are still unknown. It has been hypothesized that homocysteine might interfere with collagen cross-linking in bone, thereby weakening bone structure. Therefore, we wanted to investigate whether plasma homocysteine levels are associated with bone quality parameters, rather than with bone mineral density., Methods: Cross-sectional data of the B-PROOF study (n=1227) and of two cohorts of the Rotterdam Study (RS-I (n=2850) and RS-II (n=2023)) were used. Data on bone mineral density of the femoral neck and lumbar spine were obtained in these participants using dual-energy X-ray assessment (DXA). In addition, participants of B-PROOF and RS-I underwent quantitative ultrasound measurement of the calcaneus, as a marker for bone quality. Multiple linear regression analysis was used to investigate the associations between natural-log transformed plasma levels of homocysteine and bone mineral density or ultrasound parameters., Results: Natural-log transformed homocysteine levels were inversely associated with femoral neck bone mineral density in the two cohorts of the Rotterdam Study (B=-0.025, p=0.004 and B=-0.024, p=0.024). In B-PROOF, no association was found. Pooled data analysis showed significant associations between homocysteine and bone mineral density at both femoral neck (B=-0.032, p=0.010) and lumbar spine (B=-0.098, p=0.021). Higher natural-log transformed homocysteine levels associated significantly with lower bone ultrasound attenuation in B-PROOF (B=-3.7, p=0.009) and speed of sound in both B-PROOF (B=-8.9, p=0.001) and RS-I (B=-14.5, p=0.003), indicating lower bone quality. Pooled analysis confirmed the association between homocysteine and SOS (B=-13.1, p=0.016). Results from ANCOVA-analysis indicate that differences in SOS and BUA between participants having a plasma homocysteine level above or below median correspond to 0.14 and 0.09 SD, respectively., Discussion: In this study, plasma levels of homocysteine were significantly inversely associated with both bone ultrasound parameters and with bone mineral density. However, the size of the associations seems to be of limited clinical relevance and may therefore not explain the previously observed association between plasma homocysteine and osteoporotic fracture incidence., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
45. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
- Author
-
Roux C, Hofbauer LC, Ho PR, Wark JD, Zillikens MC, Fahrleitner-Pammer A, Hawkins F, Micaelo M, Minisola S, Papaioannou N, Stone M, Ferreira I, Siddhanti S, Wagman RB, and Brown JP
- Subjects
- Aged, Bone Density drug effects, Bone Density Conservation Agents adverse effects, Collagen Type I blood, Demography, Denosumab, Etidronic Acid therapeutic use, Female, Humans, Osteoporosis, Postmenopausal blood, Osteoporosis, Postmenopausal physiopathology, Peptides blood, Risedronic Acid, Treatment Outcome, Alendronate therapeutic use, Antibodies, Monoclonal, Humanized adverse effects, Antibodies, Monoclonal, Humanized therapeutic use, Bone Density Conservation Agents therapeutic use, Etidronic Acid analogs & derivatives, Medication Adherence, Osteoporosis, Postmenopausal drug therapy
- Abstract
Denosumab has been shown to reduce new vertebral, nonvertebral, and hip fractures in postmenopausal women with osteoporosis. In subjects who were treatment-naïve or previously treated with alendronate, denosumab was associated with greater gains in bone mineral density (BMD) and decreases in bone turnover markers when compared with alendronate-treated subjects. This trial was designed to compare the efficacy and safety of denosumab with risedronate over 12 months in postmenopausal women who transitioned from daily or weekly alendronate treatment and were considered to be suboptimally adherent to therapy. In this randomized, open-label study, postmenopausal women aged ≥55 years received denosumab 60 mg subcutaneously every 6 months or risedronate 150 mg orally every month for 12 months. Endpoints included percentage change from baseline in total hip BMD (primary endpoint), femoral neck, and lumbar spine BMD at month 12, and percentage change from baseline in sCTX-1 at months 1 and 6. Safety was also assessed. A total of 870 subjects were randomized (435, risedronate; 435, denosumab) who had a mean (SD) age of 67.7 (6.9) years, mean (SD) BMD T-scores of -1.6 (0.9), -1.9 (0.7), and -2.2 (1.2) at the total hip, femoral neck, and lumbar spine, respectively, and median sCTX-1 of 0.3 ng/mL at baseline. At month 12, denosumab significantly increased BMD compared with risedronate at the total hip (2.0% vs 0.5%), femoral neck (1.4% vs 0%), and lumbar spine (3.4% vs 1.1%; p<0.0001 at all sites). Denosumab significantly decreased sCTX-1 compared with risedronate at month 1 (median change from baseline of -78% vs -17%; p<0.0001) and month 6 (-61% vs -23%; p<0.0001). Overall and serious adverse events were similar between groups. In postmenopausal women who were suboptimally adherent to alendronate therapy, transitioning to denosumab was well tolerated and more effective than risedronate in increasing BMD and reducing bone turnover., (© 2013. Published by Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
46. [Osteoporotic vertebral fractures or Scheuermann's disease?].
- Author
-
Breda SJ, Oei HD, Oei EH, and Zillikens MC
- Subjects
- Absorptiometry, Photon, Adult, Bone Density, Bone Density Conservation Agents therapeutic use, Diagnosis, Differential, Humans, Male, Middle Aged, Osteoporotic Fractures drug therapy, Bone Density Conservation Agents adverse effects, Osteoporotic Fractures diagnosis, Scheuermann Disease diagnosis
- Abstract
A 56-year-old man was treated with bisphosphonates following incidental findings of vertebral deformities on a chest radiograph taken for cough. After re-evaluation with DEXA and spinal radiographs he was diagnosed with Scheuermann's disease, not osteoporosis. His gastrointestinal symptoms resolved after bisphosphonates were stopped. A 42-year-old man with limb-girdle muscular dystrophy and complaining of back pain underwent investigations. Radiographs showed loss of height in multiple thoracic vertebrae, yet DEXA bone mineral density was high-normal and an MRI scan suggested Scheuermann's disease. Recent osteoporotic vertebral fractures are an indication for anti-osteoporotic treatment, because they are highly predictive of future fracture risk. There are a number of differential diagnoses that should be considered in individuals with vertebral deformities, including Scheuermann's disease, especially if the clinical picture is not typically osteoporotic. This is important in order to avoid unnecessary medical treatment, which should be reserved for patients with osteoporosis. Refining vertebral fracture definitions may help to improve diagnostic accuracy.
- Published
- 2013
47. 5-HIAA excretion is not associated with bone metabolism in carcinoid syndrome patients.
- Author
-
van Dijk SC, de Herder WW, Kwekkeboom DJ, Zillikens MC, Feelders RA, van Schaik RH, van Driel M, and van Leeuwen JP
- Subjects
- Aged, Alkaline Phosphatase metabolism, Biomarkers blood, Biomarkers metabolism, Biomarkers urine, Cell Differentiation drug effects, Cell Line, Female, Humans, Male, Malignant Carcinoid Syndrome blood, Middle Aged, Osteoblasts cytology, Osteoblasts drug effects, Osteoblasts metabolism, Serotonin blood, Serotonin pharmacology, Bone and Bones metabolism, Hydroxyindoleacetic Acid urine, Malignant Carcinoid Syndrome metabolism, Malignant Carcinoid Syndrome urine
- Abstract
In patients with a carcinoid syndrome and neuroendocrine tumors of the digestive tract (carcinoids), elevated circulating serotonin (5-hydroxytryptamine, 5-HT) levels can be demonstrated. It can be hypothesized that bone metabolism will be affected in these patients, since serotonin receptors are expressed on bone cells and serotonin effects on bone have been demonstrated. However, to date, no data are available on bone metabolism parameters in patients with neuroendocrine tumors of the digestive tract (carcinoids). In the current retrospective study we have measured serum bone formation markers P1CP (pro-collagen type I C-terminal), and osteocalcin, and the bone resorption marker NTx (collagen breakdown product N-terminal), in a group of 61 carcinoid patients with increased circulating serotonin levels as demonstrated by increased excretion of the serotonin breakdown product, 5-hydroxy indole acetic acid (5-HIAA), in the urine (>50 μmol/24 h, so-called "hyper-secretors") and a control group of 23 carcinoid patients, without increased 5-HIAA excretion (so-called non-secretors). The 24-h urinary excretion of 5-HIAA reflects the 24-h production of serotonin. Measurements of markers of bone metabolism were performed in serum samples obtained before the start of medical treatment. The hypersecretor group had on average a 10-fold higher urinary 5-HIAA excretion than the control (non-secretor) group. No significant differences in bone metabolism parameters could be demonstrated between hyper-secretors and controls (non-secretors). Correlation and regression analyses could not demonstrate significant age- and sex-adjusted correlations between urinary 5-HIAA excretion and any of the markers for bone turnover. A limitation is that the exposure time to elevated levels of serotonin is unknown, which might have been too short to induce effects on bone metabolism. Treatment of human pre-osteoblasts SV-HFO with serotonin didn't change alkaline phosphatase activity throughout differentiation as well as mineralization. In conclusion, the current study in a unique group of untreated carcinoid patients could not demonstrate a major role for circulating serotonin in the control of bone metabolism., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
48. The association between plasma homocysteine levels, methylation capacity and incident osteoporotic fractures.
- Author
-
Enneman AW, van der Velde N, de Jonge R, Heil SG, Stolk L, Hofman A, Rivadeneira F, Zillikens MC, Uitterlinden AG, and van Meurs JB
- Subjects
- Aged, Bone Density, Female, Humans, Incidence, Linear Models, Methylation, Middle Aged, Netherlands epidemiology, Osteoporotic Fractures epidemiology, Proportional Hazards Models, Risk Factors, S-Adenosylhomocysteine blood, S-Adenosylmethionine blood, Homocysteine blood, Osteoporotic Fractures blood, Osteoporotic Fractures etiology
- Abstract
Background: An elevated level of plasma homocysteine (Hcy) is a known risk factor for osteoporotic fractures. In addition, Hcy is related to DNA-methylation metabolism. To determine whether the association between Hcy and fractures is explained by an altered methylation capacity, we investigated the associations between levels of s-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) and fracture risk., Methods: We studied 503 females aged 55 years and over from the Rotterdam Study (RS) in whom plasma Hcy, SAM and SAH levels were measured. Bone mineral density (BMD) at the hip was assessed using DXA. Incident fractures were recorded over a mean period of 7.0 years. Cox proportional hazards analysis and linear regression were used to assess relationships between plasma metabolite levels, incident osteoporotic fractures and BMD., Results: Over a total of 3502 person-years of follow-up, 103 subjects sustained at least one osteoporotic fracture. Whereas incidence of osteoporotic fractures was associated with quartiles of Hcy (p=0.047), it was not associated with quartiles of SAM, SAH or SAM/SAH-ratio (all p for trend>0.6). Stepwise linear regression showed that SAM/SAH-ratio, but not Hcy, was independently associated with hip BMD (β=0.073, p=0.025)., Conclusion: Since SAM, SAH and SAM/SAH-ratio were not associated with osteoporotic fractures, alterations in methylation capacity most likely do not appear to be an important factor in the association between Hcy and fractures., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
49. High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly.
- Author
-
Wassenaar MJ, Biermasz NR, Hamdy NA, Zillikens MC, van Meurs JB, Rivadeneira F, Hofman A, Uitterlinden AG, Stokkel MP, Roelfsema F, Kloppenburg M, Kroon HM, Romijn JA, and Pereira AM
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Acromegaly complications, Bone Density physiology, Spinal Fractures epidemiology, Spinal Fractures etiology
- Abstract
Objective: To establish the prevalence of osteoporosis, vertebral fractures (VFs), and non-VFs in acromegaly patients with long-term controlled disease and factors potentially influencing fracture risk., Design: Case-control study. Patients and measurements Eighty-nine patients (46% male, mean age: 58 years) were included. We studied VFs and non-VFs, bone mineral density (BMD), and markers of bone turnover. In 48 patients, BMD assessment was also obtained 7 years prior to the current study. To compare VF prevalence, data from a sample of the Dutch population (n=3469) were used., Results: VF prevalence was 59% (men 64% and women 54%), significantly increased when compared with controls (odds ratio up to 6.5), and independent of the duration of disease control, BMD, markers of bone turnover, and acromegalic disease characteristics. Mean number of VFs per patient was 3.4±0.3 (range 1-8). There was no relationship between the number and severity of fractures, parameters of bone turnover, and follow-up BMD measurements. BMD did not change during prolongation of follow-up by 7 years of controlled acromegaly., Conclusion: There is a very high prevalence of VFs in acromegaly patients with long-term controlled disease, independently of BMD. In view of the significant morbidity and mortality associated with VFs in general and the inability of BMD to predict fracture risk in acromegalic patients, we propose to include VF assessment, for example by lateral conventional radiographs of the spine in the screening of patients with acromegaly, both at diagnosis and during follow-up after establishment of disease control.
- Published
- 2011
- Full Text
- View/download PDF
50. Sex-specific genetic effects influence variation in body composition.
- Author
-
Zillikens MC, Yazdanpanah M, Pardo LM, Rivadeneira F, Aulchenko YS, Oostra BA, Uitterlinden AG, Pols HA, and van Duijn CM
- Subjects
- Female, Humans, Male, Middle Aged, Models, Genetic, Body Composition genetics, Sex Characteristics
- Abstract
Aims/hypothesis: Despite well-known sex differences in body composition it is not known whether sex-specific genetic or environmental effects contribute to these differences., Methods: We assessed body composition in 2,506 individuals, from a young Dutch genetic isolate participating in the Erasmus Rucphen Family study, by dual-energy X-ray absorptiometry and anthropometry. We used variance decomposition procedures to partition variation of body composition into genetic and environmental components common to both sexes and to men and women separately and calculated the correlation between genetic components in men and women., Results: After accounting for age, sex and inbreeding, heritability ranged from 0.39 for fat mass index to 0.84 for height. We found sex-specific genetic effects for fat percentage (fat%), lean mass, lean mass index (LMI) and fat distribution, but not for BMI and height. Genetic correlations between sexes were significantly different from 1 for fat%, lean mass, LMI, android fat, android:gynoid fat ratio and WHR, indicating that there are sex-specific genes contributing to variation of these traits. Genetic variance was significantly higher in women for the waist, hip and thigh circumference and WHR, implying that genes account for more variance of fat distribution in women than in men. Environmental variance was significantly higher in men for the android:gynoid fat ratio., Conclusions/interpretation: Sex-specific genetic effects underlie sexual dimorphism in several body composition traits. The findings are relevant for studies on the relationship of body composition with common diseases like cardiovascular disease and type 2 diabetes and for genetic association studies.
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.